HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS		QUICK SEARCH:   [advanced] Author: Keyword(s): Year:  Vol:  Page:

This Article Full Text Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Add to Personal Folders Download to citation manager Author home page(s): Derek D. Muehrcke Patrick M. McCarthy Delos M. Cosgrove Permission Requests Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Muehrcke, D. D. Articles by Cosgrove, D. M. Search for Related Content PubMed PubMed Citation Articles by Muehrcke, D. D. Articles by Cosgrove, D. M.

J Thorac Cardiovasc Surg 1996;112:472-483
© 1996 Mosby, Inc.

CARDIOPULMONARY BYPASS, MYOCARDIAL MANAGEMENT, AND SUPPORT TECHNIQUES

BIOCOMPATIBILITY OF HEPARIN-COATED EXTRACORPOREAL BYPASS CIRCUITS: A RANDOMIZED, MASKED CLINICAL TRIAL

Supported by a grant from The Baxter Corporation.

Received for publication August 4, 1995 Revisions requested Sept. 11, 1995; revisions received Oct. 3, 1995 Accepted for publication Oct. 20, 1995. Address for reprints: Derek D. Muehrcke, MD, Department of Thoracic and Cardiovascular Surgery, F-25, The Cleveland Clinic Foundation, 9500 Euclid Ave., Cleveland, OH 44195.

Abstract

Cardiopulmonary bypass circuits cause morbidity during cardiac operations. Plasma proteins and cellular components are stimulated by contact with the cardiopulmonary bypass circuit and can cause bleeding and postperfusion syndrome. This is especially true in patients undergoing reoperative cardiac procedures, which carries a higher risk of postoperative bleeding and prolonged ventilation compared with primary cardiac surgical procedures. Recently, cardiopulmonary bypass circuit surfaces have been coated with antithrombotic agents to improve their biocompatibility. This study evaluated the effect of a heparin-coated cardiopulmonary bypass system (Duraflo II, Baxter Bentley Healthcare Systems, Irvine, Calif.) on thrombin formation, platelet stimulation, and leukocyte activation in patients undergoing reoperative coronary artery bypass grafting or valve operation. Fifty patients were selected and randomly assigned to a standard noncoated control system (n = 26) or the Duraflo heparin-coated system (n = 24). Similar heparin doses were used in both groups (3 mg/kg). The heparin-coated group used a completely heparin-coated bypass circuit including the cardiotomy reservoir; arterial filters were heparin-coated in both groups. Samples were obtained before cardiopulmonary bypass, 30 minutes into cardiopulmonary bypass, 5 minutes after crossclamp removal, and 5 minutes after protamine administration. Thrombin formation (thrombin-antithrombin III by enzyme-linked immunosorbent assays) and platelet activation (ß-thromboglobulin by enzyme-linked immunosorbent assays; P-selectin expression by flow cytometry) were assayed. Leukocyte activation was determined by quantitative and qualitative analysis of arterial filters by scanning electron microscopy in six patients from each group. In both circuits, thrombin values increased markedly 30 minutes into cardiopulmonary bypass compared with baseline values (p < 0.001) (heparin-coated, 7 ± 5 to 96 ± 115 ng/ml; noncoated, 10 ± 9 to 115 ± 125 ng/ml). Platelet activation as measured byß-thromboglobulin (heparin-coated, 104 ± 100 to 284 ± 166 IU/ml; noncoated, 81 ± 74 to 288 ± 277 IU/ml) and P-selectin expression (heparin-coated, 1.5% ± 1.5% to 6.4% ± 6.1%; noncoated, 1.4% ± 1.1% to 6.2% ± 4.3%) also significantly increased 30 minutes into cardiopulmonary bypass compared with baseline values (p < 0.001). Platelet activation and thrombin generation did not differ between the two circuits at any time. Granulocyte activation and platelet deposition did not differ between the two circuits when arterial filters were evaluated. Both groups had similar heparin and protamine administration, blood transfusions, postoperative alveolar-arterial oxygen gradient, time to extubation, length of intensive care unit stay, and overall morbidity and mortality. Clinical outcome and blood loss did not differ between the groups. We conclude that heparin-coated cardiopulmonary bypass circuits did not improve biochemical or clinical markers of biocompatibility in a reoperative patient population. (J THORAC CARDIOVASC SURG 1996;112:472-83)

This article has been cited by other articles:

				J. W. Hammon Extracorporeal Circulation: The Response of Humoral and Cellular Elements of Blood to Extracorporeal Circulation Card. Surg. Adult, January 1, 2008; 3(2008): 370 - 389. [Full Text]

				O. Mangoush, S. Purkayastha, S. Haj-Yahia, J. Kinross, M. Hayward, F. Bartolozzi, A. Darzi, and T. Athanasiou Heparin-bonded circuits versus nonheparin-bonded circuits: an evaluation of their effect on clinical outcomes Eur. J. Cardiothorac. Surg., June 1, 2007; 31(6): 1058 - 1069. [Abstract] [Full Text] [PDF]

				S. Gunaydin, K. McCusker, V. Vijay, S. Isbir, T. Sari, M. A. Onur, A. Gurpinar, A. Sezgin, M. F Sargon, T. Tezcaner, et al. Comparison of polymethoxyethylacrylate-coated circuits with leukocyte filtration and reduced heparinization protocol on heparin-bonded circuits in different risk cohorts Perfusion, November 1, 2006; 21(6): 329 - 342. [Abstract] [PDF]

				K. G. Shann, D. S. Likosky, J. M. Murkin, R. A. Baker, Y. R. Baribeau, G. R. DeFoe, T. A. Dickinson, T. J. Gardner, H. P. Grocott, G. T. O'Connor, et al. An evidence-based review of the practice of cardiopulmonary bypass in adults: A focus on neurologic injury, glycemic control, hemodilution, and the inflammatory response. J. Thorac. Cardiovasc. Surg., August 1, 2006; 132(2): 283 - 290.e3. [Full Text] [PDF]

				G. M. Palatianos, C. N. Foroulis, M. I. Vassili, G. Astras, K. Triantafillou, E. Papadakis, A. A. Lidoriki, E. Iliopoulou, and E. N. Melissari A prospective, double-blind study on the efficacy of the bioline surface-heparinized extracorporeal perfusion circuit Ann. Thorac. Surg., July 1, 2003; 76(1): 129 - 135. [Abstract] [Full Text] [PDF]

				P. Menasche and L. H. Edmunds Jr. Extracorporeal Circulation: The Inflammatory Response Card. Surg. Adult, January 1, 2003; 2(2003): 349 - 360. [Full Text]

				P. Borgdorff, D. Fekkes, and G. J. Tangelder Hypotension Caused by Extracorporeal Circulation: Serotonin From Pump-Activated Platelets Triggers Nitric Oxide Release Circulation, November 12, 2002; 106(20): 2588 - 2593. [Abstract] [Full Text] [PDF]

				K. Kottke-Marchant and S. Sapatnekar Hemostatic Abnormalities in Cardiopulmonary Bypass: Pathophysiologic and Transfusion Considerations Seminars in Cardiothoracic and Vascular Anesthesia, September 1, 2001; 5(3): 187 - 206. [Abstract] [PDF]

				L.-C. Hsu Heparin-coated cardiopulmonary bypass circuits: current status Perfusion, September 1, 2001; 16(5): 417 - 428. [Abstract] [PDF]

				C. Guenther, J. Mullen, M. Bentley, A. Koshal, and B. Finegan SAFETY OF LOW DOSE HEPARINIZATION WITH HEPARIN-COATED BYPASS CIRCUITS FOR CORONARY ARTERY BYPASS SURGERY Can J Anesth, June 1, 2001; 48(90001): A65 - 65. [Full Text] [PDF]

				J.-O. Defraigne, J. Pincemail, G. Dekoster, R. Larbuisson, M. Dujardin, F. Blaffart, J.-L. David, and R. Limet SMA circuits reduce platelet consumption and platelet factor release during cardiac surgery Ann. Thorac. Surg., December 1, 2000; 70(6): 2075 - 2081. [Abstract] [Full Text] [PDF]

				P. Borgdorff, G. van den Bos, and G. J. Tangelder Extracorporeal circulation can induce hypotension by both blood-material contact and pump-induced platelet aggregation J. Thorac. Cardiovasc. Surg., July 1, 2000; 120(1): 12 - 19. [Abstract] [Full Text] [PDF]

				J.-O. Defraigne, J. Pincemail, R. Larbuisson, F. Blaffart, and R. Limet Cytokine release and neutrophil activation are not prevented by heparin-coated circuits and aprotinin administration Ann. Thorac. Surg., April 1, 2000; 69(4): 1084 - 1091. [Abstract] [Full Text] [PDF]

				P. Borgdorff, R. H. van den Berg, M. A. Vis, G. C. van den Bos, and G. J. Tangelder PUMP-INDUCED PLATELET AGGREGATION IN ALBUMIN-COATED EXTRACORPOREAL SYSTEMS J. Thorac. Cardiovasc. Surg., November 1, 1999; 118(5): 946 - 952. [Abstract] [Full Text] [PDF]

				H. P. Wendel and G. Ziemer Coating-techniques to improve the hemocompatibility of artificial devices used for extracorporeal circulation Eur. J. Cardiothorac. Surg., September 1, 1999; 16(3): 342 - 350. [Abstract] [Full Text] [PDF]

				P. M. McCarthy, J.-P. P. Yared, R. C. Foster, D. A. Ogella, J. A. Borsh, and D. M. Cosgrove III A prospective randomized trial of Duraflo II heparin-coated circuits in cardiac reoperations Ann. Thorac. Surg., May 1, 1999; 67(5): 1268 - 1273. [Abstract] [Full Text] [PDF]

				F. D. Rubens, R. S. Labow, G. R. Lavallee, M. I. Watson, J. A. Robblee, M. E. Voorhees, and H. J. Nathan Hematologic evaluation of cardiopulmonary bypass circuits prepared with a novel block copolymer Ann. Thorac. Surg., March 1, 1999; 67(3): 689 - 696. [Abstract] [Full Text] [PDF]

				C B. Mahoney Heparin-bonded circuits: clinical outcomes and costs Perfusion, May 1, 1998; 13(3): 192 - 204. [Abstract] [PDF]